Cargando…

Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor

CASE: A 39-year-old man with thymoma-associated acetylcholine receptor antibody myasthenia gravis (MG) presented with fevers, night sweats, abdominal pain and weight loss. Marked splenomegaly and intra-abdominal lymphadenopathy were found. Biopsies confirmed disseminated Mycobacterium genavense infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jessie, Nguyen, MaiAnh, Hu, Hannah, Cheong, Elaine, Sean Riminton, D, Reddel, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119138/
https://www.ncbi.nlm.nih.gov/pubmed/35663588
http://dx.doi.org/10.1136/bmjno-2022-000285
_version_ 1784710642476777472
author Chen, Jessie
Nguyen, MaiAnh
Hu, Hannah
Cheong, Elaine
Sean Riminton, D
Reddel, Stephen
author_facet Chen, Jessie
Nguyen, MaiAnh
Hu, Hannah
Cheong, Elaine
Sean Riminton, D
Reddel, Stephen
author_sort Chen, Jessie
collection PubMed
description CASE: A 39-year-old man with thymoma-associated acetylcholine receptor antibody myasthenia gravis (MG) presented with fevers, night sweats, abdominal pain and weight loss. Marked splenomegaly and intra-abdominal lymphadenopathy were found. Biopsies confirmed disseminated Mycobacterium genavense infection. Despite antimicrobials and reduced immunosuppressive medications, he worsened. We suspected a thymoma-associated cytokine inhibitory antibody. The addition of subcutaneous interferon-gamma (IFN-γ) induced clinical and radiological improvement. His antimicrobials were able to be ceased. MG remained stable. Subsequent testing demonstrated an endogenous interleukin-12 (IL-12) inhibitor, likely inhibiting the IL-12/IFN-γ axis crucial for defence against mycobacterial infections. DISCUSSION: This case illustrates the autoimmune manifestations that can occur with thymoma. It illustrates the benefit of exogenous IFN-γ in overcoming the immune deficit. In this case, its use did not exacerbate existing autoimmune disease or trigger others. We raise awareness of the need to consider cytokine pathway defects as a contributing factor to refractory atypical infections in patients with thymoma-associated MG.
format Online
Article
Text
id pubmed-9119138
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91191382022-06-04 Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor Chen, Jessie Nguyen, MaiAnh Hu, Hannah Cheong, Elaine Sean Riminton, D Reddel, Stephen BMJ Neurol Open Short Report CASE: A 39-year-old man with thymoma-associated acetylcholine receptor antibody myasthenia gravis (MG) presented with fevers, night sweats, abdominal pain and weight loss. Marked splenomegaly and intra-abdominal lymphadenopathy were found. Biopsies confirmed disseminated Mycobacterium genavense infection. Despite antimicrobials and reduced immunosuppressive medications, he worsened. We suspected a thymoma-associated cytokine inhibitory antibody. The addition of subcutaneous interferon-gamma (IFN-γ) induced clinical and radiological improvement. His antimicrobials were able to be ceased. MG remained stable. Subsequent testing demonstrated an endogenous interleukin-12 (IL-12) inhibitor, likely inhibiting the IL-12/IFN-γ axis crucial for defence against mycobacterial infections. DISCUSSION: This case illustrates the autoimmune manifestations that can occur with thymoma. It illustrates the benefit of exogenous IFN-γ in overcoming the immune deficit. In this case, its use did not exacerbate existing autoimmune disease or trigger others. We raise awareness of the need to consider cytokine pathway defects as a contributing factor to refractory atypical infections in patients with thymoma-associated MG. BMJ Publishing Group 2022-05-18 /pmc/articles/PMC9119138/ /pubmed/35663588 http://dx.doi.org/10.1136/bmjno-2022-000285 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Short Report
Chen, Jessie
Nguyen, MaiAnh
Hu, Hannah
Cheong, Elaine
Sean Riminton, D
Reddel, Stephen
Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor
title Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor
title_full Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor
title_fullStr Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor
title_full_unstemmed Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor
title_short Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor
title_sort refractory mycobacterium genavense infection secondary to thymoma-associated endogenous il-12 inhibitor
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119138/
https://www.ncbi.nlm.nih.gov/pubmed/35663588
http://dx.doi.org/10.1136/bmjno-2022-000285
work_keys_str_mv AT chenjessie refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor
AT nguyenmaianh refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor
AT huhannah refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor
AT cheongelaine refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor
AT seanrimintond refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor
AT reddelstephen refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor